A perfectly positioned whale tale sculpture stopped a Dutch metro car from plummeting to the ground
Diogo Jota’s red-hot start to life with Liverpool has given Jurgen Klopp a selection dilemma as the Portugal forward’s goal spree puts Roberto Firmino under pressure.
Vaughan, Ontario, Nov. 05, 2020 (GLOBE NEWSWIRE) — The Residential Construction Council of Ontario (RESCON) applauds the Ontario government for its strong focus on a skilled trades strategy and digital innovation.In a budget released today, the province is setting aside $500 million over four years in a new Ontario Onwards Acceleration Fund, including $60 million for 2020-2021, which it says will pilot new technologies that improve how people and businesses experience government services in Ontario.“Reducing barriers to development by cutting red tape, simplifying policies and modernizing and digitizing government services to streamline the approvals process is critical to increasing housing supply necessary to support demographic trends and improve quality of life,” said RESCON president Richard Lyall. “We have had a chronic undersupply of housing for a generation which has driven up costs.”Through the government’s Skilled Trades Strategy, the budget also focuses on key themes that are crucial to enabling the trades to be considered a viable employment option for the next generation, such as simplifying the apprenticeship system and related career pathways as well as encouraging greater employer participation. “We are heartened to see the government commit such extensive resources to the skilled trades in Ontario,” said Lyall. “This is a reflection of the province’s understanding of the importance of construction and the need for sufficient skilled trades supply over the next decade to facilitate the economic recovery and success of Ontario.” RESCON is thrilled to see the government’s prioritization on expanding pathways into the skilled trades through partnerships with OYAP and Skills Ontario. Additionally, an investment of $4.7 million to develop a digital portal to support the trades and apprenticeship system in Ontario is a crucial part in ensuring that the pathways to entering the skilled trades are as accessible as possible for interested youth. The Group Sponsorship Grant and the establishment of the Skills Development Fund will allow for construction employers, including RESCON members and sub-trades, to become more involved and engaged in recruitment and retention of our next generation of construction workers.“The funding through the Apprenticeship Capital Grant will provide significant opportunities for industry to establish training facilities with necessary modern equipment to ensure that apprentices have the tools to obtain the latest subject-matter training,” added Lyall. RESCON also commends the government for the investment of an additional $60 million to the Black Youth Action Plan. Improving and expanding partnerships with the private sector, including the residential construction industry, will ensure that our collective efforts in addressing barriers and increasing labour market participation of Black youth in the trades are impactful. “Recognizing that anti-Black racism exists in many aspects of our society, including in the construction industry, is the first step to making meaningful improvement,” said RESCON policy and programs analyst Amina Dibe. “RESCON commends the government for also recognizing this. Further, we’re engaging with government, builders, the sub-trades and labour through RESCON’s Anti-Racism Roundtable and a Construction Against Racism Everywhere, or CARE campaign.”RESCON is also pleased to see a continued focus on the mental health and wellness of all Ontarians. COVID-19 has exacerbated many mental health challenges that people face, including workers in the construction industry. Expanding access and reducing wait times to mental health and addictions support services will ensure that people are able to get help when they need it the most.Background on RESCON: The Residential Construction Council of Ontario is the province’s leading association of residential builders committed to providing leadership and fostering innovation in the industry. CONTACT: Grant Cameron RESCON 905-638-1706 [email protected]
Thomas Tuchel left Borussia Dortmund on bad terms in 2017 and there is a growing feeling that his relationship with Paris Saint-Germain could be heading for a messy divorce too.
Save on GoPro deals at the early Black Friday sale, together with HERO 5, 6, 7, 8 & 9, MAX camera, accessories & more savings Early Black Friday GoPro camera and accessory deals for 2020 have landed. Review the best discounts on the GoPro MAX, HERO 9, HERO 8, HERO 7 and more. Access the best deals using the links below.Best GoPro Deals: * Save up to $100 on a wide range GoPro HERO 9, HERO 8, HERO 7, MAX 360 action cameras & bundles at GoPro.com * Save up to $230 on GoPro HERO 8, 7, 6 & 5 action cameras and bundles at Walmart * Save up to $90 on GoPro HERO 9, HERO 8, HERO 7, HERO 6 & HERO 5 waterproof action cameras at Amazon – check deals on bundles, batteries, mounts and accessories * Save up to $113 on GoPro HERO 6 action cameras at Amazon * Save up to $178 on GoPro HERO 5 action cameras at AmazonBest GoPro Hero 9 Black Deals: * Save $50 on the GoPro HERO9 Black action camera at GoPro.com * Save up to $50 on the GoPro HERO9 Black action camera at AmazonBest GoPro Hero 8 Black Deals: * Save up to $50 on the latest GoPro HERO8 Black camera & bundles at GoPro.com * Save $50 on the latest GoPro HERO8 action camera – at Walmart * Save up to $100 on the GoPro HERO8 Black action camera at Amazon – check out the latest deals on the HERO 8 action camera & renewed modelsBest GoPro Hero 7 Deals: * Save on GoPro HERO 7 cameras, gimbals, cases & accessories – at Amazon * Save up to $130 on the GoPro HERO 7 Black, Silver & White action cameras & bundle deals at WalmartIn need of some more deals? Click here to see the entire selection of active deals at Walmart’s Black Friday sale and click here to check out Amazon’s current holiday season deals. Consumer Articles earns commissions from purchases made using the links provided.GoPro action cameras are among the best for good reason. They have excellent stabilization, high-resolution lenses, and various shooting features, such as time lapse and slo-mo. For instance, the latest model, the GoPro HERO 9 Black, is capable of capturing 5K videos at 30 fps. It also has plenty of accessories available, including the Floaty case for surfing and snorkeling and the Max Lens Mod that improves stabilization and field of view. Meanwhile, the HERO MAX can record 360-degree videos in 6K for a different level of immersion. Previous models such as the HERO 8, HERO 7, HERO 6, and HERO 5 are still worth considering too, especially now that their prices have dropped.About Consumer Articles: Consumer Articles shares informative e-commerce news. As an Amazon Associate and affiliate Consumer Articles earns from qualifying purchases.Contact: Andy Mathews ([email protected])
James Lowe once described the thought of ending up playing for Ireland as a “weird prospect”, but the highly-rated New Zealand-born wing looks set to do so during the Autumn Nations Cup.
A shockingly small number of seniors take advantage of this free service, saving hundreds on Medicare plans.
New Zealand Prime Minister Jacinda Ardern’s centre-left government has increased its parliamentary majority after the results of postal and other special circumstance votes bolstered her already decisive Oct. 17 election victory. Ardern’s Labour Party increased its majority to 65 seats from 64 in the 120-seat assembly, according to NZ Electoral Commission results released on Friday. The official results included an additional 500,000 special votes, which include ballots mailed in from overseas.
A 3-month-old Pembroke Welsh Corgi was stolen from the ARE Animal Rescue in Hemet, California, about an hour after undergoing surgery
Apple, Microsoft are flashing buy signals as the stock market rally fuels a breakout wave. Square leads earnings movers late.
Seniors on Medicare Are Getting a Nice Boost To Their Social Security Check Every Month Thanks To A New “Advantage” Policy
(Bloomberg) — ByteDance Ltd. is in discussions to raise $2 billion before listing some of its businesses in Hong Kong, people familiar with the matter said, even as it seeks to avoid a ban on its TikTok service in the U.S.The Chinese company is in talks with a group of investors including Sequoia over funding that would boost its valuation to $180 billion, the people said, asking not to be identified discussing a private deal. ByteDance could then start preparing some of its biggest assets including Douyin and Toutiao for an initial public offering in Hong Kong, the people said. The company was last valued at $140 billion, according to CB Insights.The terms of the funding round may still change as negotiations are ongoing, the people said. A representative for ByteDance declined to comment, while a representative for Sequoia didn’t immediately respond to a request for comment.ByteDance, already the world’s most valuable startup, is in the throes of fighting a Trump administration ban on TikTok in the U.S. after the video service was labeled a national security threat. It’s now seeking U.S. and Chinese government approvals for a deal to sell a stake in the app to Oracle Corp. and Walmart Inc., though negotiations have bogged down during the elections and legal battles over the implementation of the ban.TikTok, Hong Kong and More U.S.-China Flashpoints: QuickTakeThat deal, which included a condition that TikTok go public within 12 months on a U.S. exchange, won Donald Trump’s initial nod as a way to keep alive a social media phenom that’s become the go-to repository of music videos for 100 million-plus Americans. ByteDance was seeking a valuation of $60 billion for the app, Bloomberg News reported in September.While the clash in the U.S. has drawn global attention, ByteDance’s services in China remain its most lucrative. Douyin, the domestic version of TikTok, surpassed 600 million daily active users in August, up from 400 million at the start of the year. The company said this week it plans to hire 10,000 more in the world’s second-biggest economy by the end of this year.Its largest local rival Kuaishou Technology filed for a Hong Kong initial public offering on Thursday, underscoring both the eye-popping growth of the Chinese short video arena as well as ByteDance’s dominance of that scene. Kuaishou, or “fast hand,” reported about 39 billion yuan of revenue in 2019, while ByteDance was said to have generated more than $17 billion revenue in the same year. While the pre-listing document didn’t provide a fundraising target, people familiar with the matter said in September that the potential share sale could raise as much as $5 billion.Toutiao, a news service driven by artificial intelligence recommendations, was the company’s first breakout hit and has surged in popularity in China.ByteDance’s billionaire founder Zhang Yiming is still fighting to hold onto some control over TikTok, an app he built into a genuine challenger to Google and Facebook Inc. Under the proposed deal with the Trump administration, TikTok would be spun out of ByteDance, set up a global headquarters in the U.S. and sell a 20% stake to Oracle and Walmart.ByteDance has said it intends to retain the other 80%, although its partners have said the shares in the new TikTok Global would have to be distributed to ByteDance’s current shareholders. Those include American venture firms, including General Atlantic and Sequoia Capital.At the same time, ByteDance has sued the U.S. government to prevent a ban. In October, a federal judge in Pennsylvania blocked a broad set of government restrictions designed to curb the use of TikTok in the U.S.TikTok emerged as a top target in Trump’s effort to crack down on China ahead of the U.S. elections. Tensions between Washington and Beijing escalated after his administration waged a campaign to contain the country’s technology ascendancy that also ensnared Tencent Holdings Ltd., now fighting a similar executive order banning its WeChat super-app.(Updates with Kuaishou’s Hong Kong IPO filing in seventh paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Hytera, a global leading Professional Mobile Radio (PMR) solution provider, participated in Critical Communications Week (CCWeek) 2020 as a Brand Leader sponsor to showcase its latest innovations and shared perspectives on the evolution of communications technologies from 2G to 5G. CCWeek, a five-day virtual exhibition and conference on Nov. 2-6, offers a new opportunity for stakeholders of the critical communications sector to network after the Critical Communications World 2020 offline event was cancelled due to the pandemic.
Easy-to-remove barcodes and QR codes used to tag everything from T-shirts to car engines may soon be replaced by a tagging system based on DNA and invisible to the naked eye, scientists said Thursday.
Merger completed with Rexahn Pharmaceuticals creating a Nasdaq-listed Biopharmaceutical Company Focused on Advancing Ocuphire’s Late-Stage Clinical Pipeline of Ophthalmic Drug Candidates Trading under “OCUP” on the Nasdaq Capital Market to begin November 6, 2020Concurrent $21.15 Million Private Placement led by Institutional Healthcare and Accredited InvestorsConference Call and Live Webcast on Friday, November 6, 2020, at 11 AM Eastern TimeFARMINGTON HILLS, Mich., Nov. 05, 2020 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, is pleased to announce the completion of its previously announced merger with Rexahn Pharmaceuticals, Inc. (NasdaqCM: REXN). The combined company will operate under the name Ocuphire Pharma. Its shares will commence trading on the Nasdaq Capital Market and will reflect a 1-for-4 reverse stock split at the open of trading on November 6, 2020, under the ticker symbol “OCUP”.In addition, the Company has announced the closing of the previously announced $21.15 million private placement, with certain institutional healthcare investors led by Altium Capital, accredited investors, and directors and officers of Ocuphire (the “Investors”). Pursuant to this transaction, Ocuphire issued to the Investors shares of Ocuphire common stock immediately prior to the merger and agreed to issue to the Investors warrants to purchase shares of common stock. At closing as a result of the transactions, Ocuphire stockholders including the Investors, own approximately 86.6% of the fully-diluted shares outstanding, with Rexahn stockholders owning approximately 13.4% of the fully-diluted shares outstanding. As of the closing of the merger, there were 7,091,878 shares of common stock outstanding. Based on the $21.15 million purchase price of the private placement, the 1,249,996 shares of the combined company owned by the Investors had an effective price per share of $16.92 per share. Additional shares are held in escrow, which may be released in whole or in part to the Investors or returned to the Company. In addition, each Rexahn stockholder is being issued one contingent value right per post-split share owned, representing the right to receive, during the 15-year period after the closing of the merger, a pro rata share of certain contingent payments, to the extent received by Ocuphire, under Rexahn’s prior license agreements or relating to Rexahn’s intellectual property, less certain permitted deductions. Cantor Fitzgerald & Co. and Canaccord Genuity LLC acted as co-lead placement agents and financial advisors to Ocuphire in connection with the private placement, and Honigman LLP is serving as legal counsel to Ocuphire. Oppenheimer & Co. Inc. acted as financial advisor to Rexahn for the merger transaction, and Hogan Lovells US LLP is serving as legal counsel to Rexahn.“We are thrilled to complete this merger, which creates a publicly listed biopharmaceutical company focused on developing and commercializing therapies for the treatment of eye disorders,” said Mina Sooch, President and CEO of Ocuphire. “We believe the target product profiles of our two ophthalmic candidates, Nyxol and APX3330, collectively studied in 18 clinical trials and each having market potential, create an opportunity for Ocuphire to become a leading ophthalmic company focused on improving vision and clarity. We look forward to multiple Phase 3 and Phase 2 clinical data readouts in 2021.”Ocuphire has built a pipeline of multiple product candidates with demonstrated clinical activity that targets high value markets. Its lead product candidate, Nyxol® Eye Drops (“Nyxol”), is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for three distinct indications for which Nyxol could be the first approved pharmacological therapy, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to target multiple disease pathways that contribute to the pathology of diabetic retinopathy (DR) and diabetic macular edema (DME).Ocuphire held its end of phase 2 (EOP2) meeting with the FDA in May 2020 to discuss the regulatory pathway for Nyxol in multiple chronic and acute refractive indications. Building on the guidance from the EOP2 meeting and the recent ORION-1 and MIRA-1 clinical trials, Ocuphire has designed its upcoming Phase 3 registration trials accordingly.Overall, the company plans to initiate two Phase 3 registration trials and two Phase 2 trials across four ophthalmic indications in the fourth quarter of 2020 and the first quarter of 2021. Given the opportunity for faster, shorter ophthalmic clinical trials, data readouts are expected throughout 2021.Ocuphire’s leadership team is comprised of seasoned professionals with decades of experience in the pharmaceutical, biotech, and medical research industries. The senior management team will be comprised of Mina Sooch, President and CEO; Charlie Hoffmann, VP of Corporate Development and Operations; Amy Rabourn, VP of Finance; Konstantinos Charizanis, Senior Director of Market Strategy and R&D; Drey Coleman, Director of Clinical Operations and Vendor Management; and Daniela Oniciu, Head of CMC and Global Supply Manufacturing. Cam Gallagher serves as the Chairman of the Board, with Mina Sooch serving as Vice Chair of the Board and Sean Ainsworth, James Manuso, Alan Meyer, Susan Benton and Rick Rodgers serving as Board members. Ocuphire has also continued to build out its Medical Advisory Board with world-class refractive and retina physicians including Drs. Michael Allingham, David Boyer, Jack Holladay, Edward Holland, Gerald Horn, Peter Kaiser, Paul Karpecki, Mark Kelley, Eliot Lazar, Richard Lindstrom, Marguerite McDonald, Jay Pepose, Thomas Samuelson and Jeffrey Heier.Conference Call and Webcast Details:Management will host a conference call and webcast with slides at 11:00 AM Eastern Time on Friday, November 6, 2020, for investors regarding this announcement with details as follows:Dial in (domestic):877-407-4018 International:201-689-8471 Conference ID:13712275 Webcast:http://public.viavid.com/index.php?id=142102 The archived webcast will be available on the Investors section of the Ocuphire website.About Ocuphire PharmaOcuphire is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late stage development, regulatory preparation, and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s clinical trials. For more information, please visit www.ocuphire.com.Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates and potential. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; (ii) the success and timing of regulatory submissions and pre-clinical and clinical trials; (iii) regulatory requirements or developments; (iv) changes to clinical trial designs and regulatory pathways; (v) changes in capital resource requirements; (vi) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vii) legislative, regulatory, political and economic developments, and (viii) the effects of COVID-19 on clinical programs and business operations. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC (including the proxy statement/prospectus included in that certain Registration Statement on Form S-4 (File No. 333-239702) initially filed with the SEC on July 6, 2020 and declared effective by the SEC on October 2, 2020. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.Investor Contacts:Mina Sooch, CEO Ocuphire Pharma, Inc. [email protected] Davis, Ph.D. LifeSci Advisors [email protected]
ACL Airshop, a technology-enabled leader in air cargo ULD* logistics solutions, has won the Air Cargo News magazine’s Innovation Award in the ULD category for the FindMyULD app. At this year’s virtual event, ACL Airshop was one of three nominees in this category amongst VRR and SkyPooling. This award was open to any businesses providing innovative products, services or operations that are helping to transform the air cargo industry.
Our experts have thoroughly tested the most common antivirus softwares in the market. Here are their top 5 picks.
Get a head-start on holiday shopping with Best Buy’s Wish List Sale, with Black Friday 2020 discounts on Amazon devices, Apple watches and more.
In the days since an inconclusive election night likely threw his presidency into the heap of one-termers, Donald Trump and some of his top political advisers have found another scapegoat to groan about: William Barr’s insufficiently subservient Justice Department.As his team began launching legal and public-relations blitzes in several key states and contesting the still-undetermined 2020 presidential election this week, the president has grown impatient with the Department of Justice and its seeming unwillingness to immediately intervene on Team Trump’s behalf, according to two people familiar with his private comments. “Why isn’t [DOJ] on this?” Trump asked, during one of many recent tirades about his baseless claim that the Democrats are somehow stealing the election.The president and his advisers’ displeasure at the Justice Department—which, to be clear, as part of the federal government is not supposed to be an adjunct of a particular political campaign—is another sign that the upper ranks of Trumpworld are desperately hoping that someone or something, somewhere, will come to their rescue and deliver a second term.Asked if she believes the Justice Department should intervene pronto, Jenna Ellis, a senior legal adviser to Trump and his reelection campaign, simply replied on Thursday, “That’s not my call,” adding that “the campaign is working to protect election integrity and ensure that every legal vote counts.”Still, the desire within Trump’s senior staff for a swift intervention by Attorney General Barr was palpable on Thursday. As one senior aide on Team Trump tersely put it: “Our campaign sure does! We’re frustrated.” Asked by The Daily Beast about whether or not the Department of Justice should swoop in, John Dowd, who repped the president during the Mueller probe and remains an informal legal adviser to Trump, responded, “I hope so. I hope they’re on the job.”Florida Man Spouts Conspiracy Theories About 2020 VoteThe Trump campaign had filed lawsuits to halt vote counting in Michigan, Pennsylvania and Georgia when the president’s son tweeted for federal assistance. “Where is he** is the @FBI & @TheJusticeDept?” Eric Trump demanded to know Thursday.That doesn’t mean the help won’t come eventually. Some Justice Department officials, particularly those who consider Attorney General Bill Barr little more than a Trumpist enforcer, have long predicted that senior Justice Department leadership would not sit on the sidelines while the Trump campaign contests election counts in court.“The fact we haven’t seen it yet is not a comfort. Contorted constitutional-legal theories are Barr’s preferred modus operandi,” said a current federal prosecutor on condition of anonymity.And while it hasn’t filed a motion to intervene so far, the Justice Department has tentatively waded into the campaign muck. A senior official, Richard Donoghue, informed federal prosecutors the morning after election night that the department reserves the right to order “armed federal law enforcement” to ballot-counting locations on the grounds of investigating potential vote fraud, the New York Times reported. Yet there has been no credible evidence of voter fraud, only a repeated insistence by the Trump campaign. In Georgia on Thursday, the first lawsuit filed by the campaign to stop the count was dismissed for baselessness in alleging misconduct.It was only the latest instance of Barr’s Justice Department echoing the Trump campaign line. In late September, the department announced federal prosecutors in Pennsylvania’s Luzerne County were probing “potential issues with a small number of mail-in ballots” it explicitly claimed were Trump votes. State officials days later stated flatly that an error, not fraud, resulted in nine discarded military ballots.Barr himself blazed the trail. Earlier in September, Barr falsely claimed to have indicted someone in Texas for falsifying 1,700 ballots. In reality, a Justice Department investigation of the incident found no fraud and pursued no charges. Barr’s office conceded the error.The Justice Department did not respond to a request for comment. The FBI declined and referred comment to the Justice Department. Trump campaign and White House spokespeople did not immediately respond, either.One factor inhibiting Justice Department intervention is the contradictory strategies pursued by Trump and his supporters in the various states where it suits them. In Georgia, Pennsylvania and Michigan—states where Joe Biden either has taken a lead or where still-unreported counties are expected to favor Biden—the campaign wants the count to stop. But in Arizona, where Trump expects unreported ballots to favor him, Trump supporters have been demanding to proceed with the count.Intervention at such a fluid time runs the risk of federal courts establishing a rule that would work to the Trump campaign’s disadvantage in a different state. Incoherent legal approaches also risk putting federal judges—as well as Trump appointees to the Supreme Court—in untenable positions that might not yield the result Trump wants.Barr, the federal prosecutor believes, prefers to “give the appearance that DOJ is not appearing in frivolous Giuliani lawsuits, or seen to be on the side of Eric Trump. He wants to give the impression that DOJ is restrained and responsible, and then when all votes are counted and he figures out which states matter, then he will invent some contorted legal theory that suits the facts of the states that matter for Trump.”The prosecutor continued: “However contorted and meritless a legal theory Barr wants to press, he does know that whatever it is, it has to be consistent, and he can’t know what position to take right now. But you’ll know pretty soon.”Elie Honig, the former federal prosecutor and CNN legal analyst, said any intervention from Barr would come only if the balloting margins are small enough that it could determine the outcome. If so, Barr would likely “lend DOJ’s heft” to Trump’s court cases, said Honig, who next year will publish a book about Barr and his legacy at Main Justice, “Hatchet Man.”Outside of that, Barr could also push Trump’s lines about voter fraud. “Thus far, Barr has tried mightily to prop up the fraud narrative with a series of unsupported or untrue public statements. It seems there’s just nothing there, but he could keep trying,” Honig said.As the Luzerne County example indicates, some U.S. attorneys, particularly in Pennsylvania, may be eager to jump into the fray. William McSwain, the federal prosecutor in Philadelphia, where Trump supporters are demanding access to the ballot count, last year baselessly accused the Philadelphia district attorney of being “Soros-funded.” A recent profile in Philadelphia magazine described McSwain, a relentless backer of the police, as likely to seek a GOP nomination for higher office.And on Thursday night, the local Republican Party gave the Justice Department an invitation to intervene in the election. “Our lawyers just sent a criminal referral to AG Barr regarding at least 3,062 instances of voter fraud,” the party tweeted.Trump Wanted Top Notch Re-Election Lawyers. He Got a MAGA Clown Show.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
It is now my pleasure to introduce your host Tom Long, chief financial officer. On an incurred basis, we had excess DCF of nearly$550 million after distributions of $412 million and a growth capital of approximately $730 million.
This is Danielle Sheer, and I’m joined by Rob Eberle, Bottomline’s CEO; and Rick Booth, the CFO. All such forward-looking statements are subject to risks, uncertainties and assumptions, including those related to the impacts of COVID-19 on our business and global economic conditions.
Joining me on today’s call is Barry McCarthy, our President and Chief Executive Officer; Keith Bush, our Chief Financial Officer; and Heather Davis, our new Head of Investor Relations. At the end of today’s prepared remarks, we will take questions.
Whales, Humpback whale, Kayak, California
World news – US – A metro car was saved from plummeting to the ground by a whale tale sculpture